By Fineline Cube 
China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) to evaluate ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), in combination with MSD’s anti-PD-1 therapy, Keytruda (pembrolizumab). The collaboration aims to assess the treatment’s efficacy in patients with advanced solid tumors.
ATG-022 Global Positioning
ATG-022 stands out in the global landscape, with data supporting significant efficacy across all levels of Claudin 18.2 expression in gastric cancer, including high, low, and ultra-low expressors. This broad-spectrum activity positions ATG-022 as a promising treatment for a wider patient population compared to other CLDN18.2-targeting therapies.
Clinical Trial Results
Results from the ongoing Phase I/II CLINCH study demonstrated an objective response rate (ORR) of 42.9% and a disease control rate (DCR) of 95.2% in patients with moderate to high CLDN18.2 expression (IHC 2+ ≥ 20%). Additionally, the study showed an ORR of 30.0% and a DCR of 50.0% in patients with low CLDN18.2 expression (IHC 2+ < 20%). ATG-022 also exhibited a favorable safety profile and extended treatment durations.-Fineline Info & Tech